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Abstract
Recent progress of genetic studies has dramatically unveiled pathogenesis of acute myeloid 
leukemia (AML). However, overall survival of AML still remains unsatisfactory and development 
of novel therapeutics is required. CCAAT/Enhancer Binding Protein α (C/EBPα) is one of crucial 
transcription factors that induce granulocytic differentiation and its activity is perturbed in human 
myeloid leukemias. As its re-expression can induce differentiation and subsequent apoptosis of 
leukemic cells in vitro, we hypothesized that chemical compounds that restore C/EBPα expression 
and/or activity would lead to myeloid differentiation of leukemic cells. Using a cell-based high-
throughput screening, we identified 2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3-(2-
methoxyphenyl)-4(3H)-quinazolinone as a potent inducer of C/EBPα and myeloid differentiation. 
Leukemia cell lines and primary blast cells isolated from human AML patients treated with 
ICCB280 demonstrated evidence of morphological and functional differentiation, as well as 
massive apoptosis. We performed conformational analyses of the high-throughput screening hit 
compounds to postulate the spatial requirements for high potency. Our results warrant a 
development of novel differentiation therapies and significantly impact care of AML patients with 
unfavorable prognosis in the near future.
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Recent advances in genetic studies led to a dramatic progress in understanding the 
pathogenesis of acute myeloid leukemia (AML). However, long-term survival of AML still 
remains unsatisfactory. In particular, AMLs with monosomal or complex karyotypes have 
shown the worst prognosis with 3-year rate of overall survival being only 12%.1 Moreover, 
AMLs arising from myelodysplastic syndrome (MDS) or secondary to previous cytotoxic 
chemotherapy have a lower rate of remission than de novo AMLs. Patients with high-risk 
MDS have a 3-year survival rate of less than 10%.2 Considering the fact that conventional 
chemotherapies do not have specific targets and demonstrate various levels of toxicity, there 
is a great demand for novel targeted therapeutics. One of the best approaches is to focus on a 
block of differentiation, which is a hallmark of all subtypes of AML. All-trans retinoic acid 
(ATRA) is now widely used as the first line therapy for one subtype of AML, t(15;17) 
positive acute promyelocytic leukemia (APL), and induces differentiation of leukemia cells 
and eventually leads to apoptosis. Although it has been shown that ATRA can induce 
remission and lead to cure in nearly 70% of patients with APL,3 its application in other 
types of myeloid leukemia is limited. In addition, relapse can occur in the course of 
treatment. Although arsenic trioxide has a high rate (85%) of successful remission induction 
in patients with APL resistant to ATRA, an 18-month relapse-free survival is 60%.4
Expression of CCAAT/Enhancer Binding Protein α (C/EBPα) is increased and maintained 
during granulocytic differentiation and rapidly downregulated during the alternative 
monocytic pathway.5 Conditional expression of C/EBPα in stably transfected myeloid 
precursor cells triggers neutrophilic differentiation, concomitant with upregulation of the 
granulocyte colony-stimulating factor receptor (G-CSFR) and secondary granule proteins.5 
In mice deficient in C/EBPα, there is a block in granulocytic differentiation at the 
myeloblast stage, while all the other blood cell types are present and intact.6 Thus, C/EBPα 
is necessary and sufficient for neutrophil differentiation. Consistent with its importance in 
normal myeloid differentiation, expression and/or function of C/EBPα are perturbed in 
various types of myeloid leukemias by different mechanisms (transcriptional silencing, 
translational inhibition, posttranslational modification, decrease in DNA binding, or point 
mutations resulting in increased production of a dominant negative form).7 Thus, restoration 
of C/EBPα expression and/or activity could overcome the block of differentiation and lead 
to growth arrest and apoptosis of leukemic cells.
In the current study, we established a stable cell line carrying luciferase gene driven by an 
artificial promoter composed of a tetramer of C/EBP binding sites, which responds to C/
EBPα activity. By using this indicator line in a cell-based high-throughput screen, we 
identified one chemical compound, 2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3-(2-
methoxyphenyl)-4(3H)-quinazolinone (referred to as ICCB280), which induced myeloid 
differentiation of leukemia cell lines by increasing expression of C/EBPα and C/EBPε, and 
decreasing expression of c-Myc. Importantly, exposure of primary blast cells from AML 
patients to ICCB280 led to differentiation and apoptosis as well. Interestingly, G-CSFR, 
which is one of targets of C/EBPα, was upregulated by the treatment with ICCB280 and the 
addition of G-CSF further enhanced the differentiation induced by this compound. These 
results indicate that the use of ICCB280 alone, or in combination with other agents, such as 
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G-CSF may provide a novel means of treatment of AML. Given the fact that in addition to 
AML, abnormalities in C/EBPα expression and/or function have been also reported in other 
malignancies such as lung8 and liver,9 we believe that small molecule agents that selectively 
target C/EBPα, such as ICB280, may find broad applications in treating cancers.
Materials and Methods
Reagents
ATRA (cat. R2625) was purchased from Sigma. 2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3-(2-
methoxyphenyl)-4(3H)-quinazolinone (ICCB280) was purchased from ChemBridge (San 
Diego, CA). Stock solutions for the compounds were prepared in dimethyl sulfoxide 
(DMSO) and stored at −20°C. The drugs were diluted in fresh medium before each 
experiment, and the final DMSO concentration was <0.5%.
Determination of the purity and molecular weight of ICCB280
HPLC-MS analysis was performed with a Waters Alliance-Micromass ZQ instrument, an 
ESI source, and Waters 2489 UV/visible detector at 254 nm. Analysis was performed using 
an analytical Waters Symmetry C18 column (3.5 mm, 2.1×100 mm) operating at 0.5 
mL/min with a linear gradient of 0–100% of acetonitrile in water (containing 0.1% formic 
acid, v/v) over 10 minuites.
Cells
HL-60 (ATCC; CCL-240), K562 (ATCC; CCL-243), and U937 (ATCC; CRL-1593.2) cells 
were maintained in RPMI 1640 with 10% fetal bovine serum at 37°C with 5% CO2. CV-1 
(ATCC; CCL-70) and 293T (ATCC; CRL-3216) were maintained in DMEM with 10% fetal 
bovine serum. Primary AML patient blasts were collected from peripheral blood after 
obtaining patients’ informed consents, which were approved by the Institutional Review 
Boards at Beth Israel Deaconess Medical Center. Patient #0502 was diagnosed as acute 
myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carried inv(16)
(p13;q22). Patient #0505 was diagnosed as acute monocytic leukemia (M5) with normal 
karyotype. Mutations in the CEBPA gene were reported in neither patient. Primary AML 
blast cells were isolated using Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ), 
as previously described10 and maintained in culture in RPMI 1640 with 10% fetal bovine 
serum in the presence of G-CSF (60 ng/ml) at 37°C with 5% CO2.
Plasmid constructs
Firefly luciferase gene controlled by a minimal thymidine kinase (TK) promoter and a 
tetramer of C/EBP-binding sites from the human G-CSFR promoter (4xCEBP-luc) was 
previously described.11 To make 4x mutCEBP-luc, oligonucleotides containing mutations 
abolishing C/EBP binding (AAGGTGTTGCAATCCCCAGC → 
AAGGTGTTcaccaaCCCAGC; wild type C/EBP site underlined; mutated nucleotides in 
small letters) were tetramerized and inserted into SalI site of pTK min-luc 12 and pRL-TK 
(Promega, Madison, WI). The pGhU6 lentiviral shRNA vectors against CEBPA and the 
nonsilencing control were previously described.13
Radomska et al. Page 3













Generation of the C/EBP activity indicator cell line
U937 cells were co-transfected with the ScaI-linearized 4xCEBP-luc construct together with 
the linearized plasmid containing neomycin-resistant gene (pSV40-neo) by electroporation 
using 250 V and 960 μF in Gene Pulser II (BioRad, Hercules, CA), followed by selection in 
1 mg/ml G418. Single clones were isolated by limiting dilution in 96-well plates.
Generation of HL-60 cells stably expressing shRNAs against CEBPA
293T cells were cotransfected with C/EBPα shRNA in pGhU6 vector or the shRNA control 
and lentiviral constructs Gag-Pol and Env. HL-60 cells were then infected with virus that 
was harvested and concentrated using a Centricon Plus-70 100000 MWCO column 
(Millipore, Billerica, MA). Infected cells were detected by EGFP flow cytometry analysis.
High-throughput screening of chemical libraries
Stable U937-C/EBP clones were maintained in the RPMI 1640 phenol red-free medium, 
10% FBS, 100 U/ml penicillin G, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B, and 1 
mg/ml G418 for selective propagation. Thirty μl per well (2,400 cells) of U937-C/EBP cells 
were plated in 384-well, flat bottom, white polystyrene plates (Nalgene, Rochester, NY). All 
plates were prepared in duplicates. Assay plates were then incubated in 5% CO2 and 37°C 
for 24 hours. Next, 100 nano-litter of each compound dissolved in DMSO was added by a 
pin-transfer robot to give concentrations of 10–30 μM. ATRA and DMSO were added in 
every plate as positive and negative controls, respectively. Plates were incubated in 5% CO2 
and 37°C for another 24 hours, followed by the addition of 30 μl of Bright Glo (Promega, 
Madison, WI) to each well. Plates were incubated at room temperature for at least 3 minutes 
and the luciferase activity was read in sequential order using the LJL Analyst Reader 
(Molecular Devices, Sunnyvale CA) in Luminescence mode. The plates we screened are as 
follows: ICCB Bioactives 1; NINDS Custom Collection; SpecPlus Collection; ChemBridge 
Microformat; Commercial Diversity Set 1; Philippines Plant Extracts 1&2; Starr Foundation 
Extracts 1; ICCB Discretes 3&4; and DOS Collection (http://iccb.med.harvard.edu/retired-
compound-libraries/). All equipment and robotic instrumentation used for screening was 
provided by the Institute of Chemistry and Cell Biology (ICCB) at Harvard Medical School 
(http://iccb.med.harvard.edu/).
Nitroblue tetrazolium (NBT) reduction assay
Reduction of NBT by respiratory burst products was performed as previously described.5
Growth Inhibition Assay
Cells were plated at 10,000 cells/well with specified concentrations of compounds and 
incubated for 48 hours. Growth inhibition was assessed by MTS assay using CellTiter 96 
AQueous One solution proliferation kit (Promega). IC50 was calculated using Prism 
software (GraphPad Software, La Jolla, CA).
RNA isolation, Northern blot analysis, and quantitative real-time PCR (qRT-PCR) analysis
Total RNA was isolated by RNAeasy kit (Qiagen, Valencia, CA) according to manufacturer 
instruction. In each lane, 20 μg of RNA denatured in formamide was fractionated on 1% 
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agarose-2.2 M formaldehyde gels. RNA was transferred to Nylon membranes and probed as 
described previously.5 Membranes were hybridized with probes for human G-CSFR5 and c-
Myc.14 To ensure uniform levels and integrity of RNA samples loaded in each lane, the blot 
was stripped and rehybridized to probes specific for GAPDH.15 Quantitative RT-PCR 
analysis was performed as previously described.13
Protein sample preparation and Western blotting
Whole cell lysates were prepared in cell lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
mM NaF, protease inhibitor cocktail set III (Millipore), and 1 mM PMSF). Lysates were 
cleared by centrifugation (14,000 g for 5 minutes in a pre-cooled centrifuge) and boiled with 
Laemmli sample buffer for 3 minutes. Protein lysates (10–30 μg) were loaded on SDS/
polyacrylamide gels and blotted onto PVDF membranes (Millipore). Antibodies against C/
EBPα (sc-61), C/EBPβ (sc-150), C/EBPε (sc-158), Sp-1 (sc-59), and c-Myc (sc-40) were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). β-Actin antibody was from 
Sigma-Aldrich (A5316). All antibodies were used at 1:1000 dilution.
Apoptosis Analysis
Apoptosis was assessed using an Annexin-V-FLUOS staining kit (Roche, Penzberg, 
Germany) according to the manufacturer’s instructions.
Conformational analysis
Energy-minimized conformers for the three isomeric molecules (ICCB280 and its meta- or 
para-methoxy isomer) were generated in silico. Structures were first drawn using 
Marvinsketch (Marvin 6.2.2, 2014, ChemAxon, Budapest, Hungary) and then converted into 
protein data bank format using the Open Babel molecular toolkit.16 To reduce the necessary 
processing power, an initial steepest descent geometry optimization was performed using a 
MMFF94 forcefield (250 steps). Following the initial optimization, a weighted rotor 
conformer search was performed (200 iterations), followed by a conjugate gradient 
geometry optimization (250 steps) to generate the final 3D conformational structure of each 
isomer. Each structure was visualized and angles were calculated using the PyMOL 
molecular viewing program (Version 1.5.0.4, Schrödinger, LLC, New York, NY).
Statistical Analysis
Differences between the experimental groups were compared using Student’s t-test. P-values 
of less than 0.05 were considered statistically significant.
Results
Establishment of the cell-based high-throughput drug screen for inducers of C/EBPα 
activity
In order to detect C/EBPα activity, we designed a luciferase construct (4xC/EBP-luc), in 
which a firefly luciferase gene was placed under control of a tetramer of C/EBP binding 
sites from the human G-CSFR gene promoter upstream from the minimal thymidine kinase 
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(TK) promoter (Fig. 1A). The response of this reporter was tested in transient co-
transfection assays in CV-1cells. As shown in Figure 1B, addition of C/EBPα expression 
vector increased the luciferase activity 10-fold. We then transfected U937 human AML cells 
with the 4xC/EBP-luc construct to generate a stable cell line (U937-C/EBP). Multiple 
individual clones were isolated and subcloned at limiting dilution. It has been published 
before that treatment of U937 cells with ATRA increases levels and DNA-binding activity 
of C/EBPα.5, 17, 18 Therefore, several stable clones were tested for the response of luciferase 
activity to treatment with ATRA (Fig. 1C) and clone #10 was chosen for the high-
throughput screening. Of note is that clones that harbor the mutated C/EBP binding sites 
showed no increase in luciferase activity upon ATRA exposure (Fig. 1C), indicating that an 
increase in luciferase activity in ATRA-treated U937-C/EBP cells is specific for C/EBP 
proteins.
A detailed timeline of the high throughput screen is shown in Supplemental Figure S1. To 
optimize the assay, we plated various concentrations of U937-C/EBP cells on 384-well 
plates and treated them with DMSO (negative control), or ATRA (positive control). As 
illustrated in Figure 2A, ATRA treatment of 24,000 or 30,000 cells per well led to a 6-fold 
increase in luciferase activity, while no loss of cell viability was achieved by the treatment 
of 24,000 cells per well compared to 22% decrease in 30,000 cells per well. We therefore 
chose to use 24,000 cells per well for the actual drug screen. Chemical compounds were 
added by a pin-transfer robot to yield a final concentration of 10–30 μM. A compound was 
considered positive if its z-score was 3 or higher. For example, ATRA used as a positive 
control had a z-score of 5. A library of 67,847 compounds was screened and 320 compounds 
(0.47%) were found to significantly increase luciferase activity. Among them, 2-[(E)-2-(3,4-
dihydroxyphenyl)vinyl]-3-(2-methoxyphenyl)-4(3H)-quinazolinone (Screen number 280, 
from now on referred to as ICCB280) displayed the strongest luciferase-inducing activity 
(Fig. 2B). We repurchased the compound from the supplier (ChemBridge) and confirmed its 
molecular mass and the purity by liquid chromatographic mass spectroscopy (LCMS) 
(Suppl. Fig. S2).
ICCB280 induces granulocytic differentiation, growth arrest, and subsequent apoptosis of 
leukemia cells
Out of the 320 initial hits, we proceeded to a second screen to identify compounds that have 
the ability to induce granulocytic differentiation. We used HL-60 leukemic cell line as it has 
been extensively used as a model for myeloid differentiation for over 30 years.19 We treated 
HL-60 cells with individual compounds at 10 μM each and examined Wright-Giemsa 
stained cytospins for morphological changes. We also performed nitroblue tetrazolium 
reduction (NBT) assay detecting production of superoxide anion, which indicates functional 
maturation of leukemic cells to granulocytes. The strongest differentiation-promoting 
activity was demonstrated for ICCB280 (Fig. 3A). Seven-day treatment with ICCB280 
induced granulocyte-like morphological changes such as decrease in nucleus-to-cytoplasm 
(N/C) ratio and nuclear lobulation in 83% of the cells, whereas no cells showed granulocyte-
like morphology in cells treated with DMSO (Fig. 3B, left panels). Approximately 46% of 
the cells were also positive in NBT assay, compared to 1% of DMSO-treated control cells 
(Fig. 3B, lower right panel, black arrows). In addition, ICCB280 induced an increase in 
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surface CD11b expression, which is one of characteristics of neutrophilic differentiation 
(Fig. 5B). Furthermore, treatment of HL-60 cells with ICCB280 suppressed the cell growth 
in 48 hours, as assessed by MTS assay (Fig. 3C).
Once differentiated, neutrophils have a half-life of only 6–10 hours in the circulation and are 
eventually cleared by constitutive apoptosis.10 Therefore, induction of the differentiation-
induced apoptosis would be a key to eliminate leukemic cells in differentiation therapies. To 
examine whether ICCB280 induces apoptosis, HL-60 cells were treated with ICCB280 and 
apoptosis was assessed by AnnexinV assay. An increase in early apoptotic cells 
(AnnexinV+/PI−) was followed by that of late apoptotic cells (AnnexinV+/PI+), indicating 
that cell death was indeed caused by apoptosis (Fig. 3D). Furthermore, 41% of cells treated 
with ICCB280 for 7 days underwent apoptotic cell death (late apoptotic cells) (Fig. 3D). 
These results indicate that differentiated cells induced by ICCB280 eventually undergo 
apoptosis.
In order to confirm that ICCB280 has therapeutic potential, we treated two samples of 
primary human acute leukemia cells with ICCB280 in vitro. Leukemic blasts were isolated 
from either bone marrow or peripheral blood from patients with acute myeloid leukemia 
subtype M4 or M5, in which ATRA is not effective. After a 5-day treatment with ICCB280, 
leukemic cells showed a decrease in N/C (Fig. 3E) in 90% the cells. Moreover, Annexin V 
assay showed that ICCB280 induced more cell death than DMSO vehicle control (Suppl. 
Fig. S3), possibly due to differentiation-induced apoptosis. Taken together, these results 
indicate that ICCB280 induces granulocytic differentiation, growth arrest, and subsequent 
apoptosis in myeloid leukemia cells.
ICCB280 induces upregulation of C/EBPα and C/EBPε, but not C/EBPβ
Since the high-throughput screen was specifically designed to induce C/EBPα expression/
activity, we sought to determine whether the differentiation-promoting effect of ICCB280 
leukemic cells was indeed mediated by C/EBP proteins. All C/EBP family members have 
the capacity to bind to the G-CSFR promoter-derived C/EBP site. Therefore, in addition to 
C/EBPα, we also examined two other C/EBP family members, C/EBPβ and C/EBPε. It has 
been show that in the absence of C/EBPα, C/EBPβ can induce emergency granulocytic 
differentiation by cytokine stimulation.20 C/EBPε on the other hand is induced by C/EBPα21 
and is required for terminal neutrophilic maturation.22 When HL60 cells were treated with 
ICCB280, a time-dependent increase in CEBPA mRNA was detected by quantitative RT-
PCR (Fig. 4A). Consistent with this data, upregulation of C/EBPα protein was observed as 
early as on day 4, followed by increase in C/EBPε on day 6 (Fig. 4B). In contrast, no 
changes in C/EBPβ expression were noted through the 8 days of the experiment, as 
compared to control cells (Fig. 4B). T These results demonstrate that ICCB280 upregulates 
C/EBPα at the transcriptional level.
ICCB280 modulates expression of C/EBPα target genes
Next, we examined whether ICCB280 alters expression of downstream targets of C/EBPα. 
Northern blot analysis demonstrated that mRNA expression of G-CSFR (CSF3R), which is a 
known target of C/EBPα, is rapidly upregulated in cells treated with ICCB280 (Fig. 4C). In 
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contrast, both c-Myc mRNA and its protein were strongly downregulated by ICCB280 (Fig. 
4C and Suppl. Fig. S4). This result is consistent with the previous report demonstrating that 
c-Myc expression is negatively regulated by C/EBPα.14 Next, we asked whether 
upregulation of C/EBPα is necessary for ICCB280-induced differentiation. To this end, we 
generated HL-60 cells expressing shRNA against CEBPA. HL-60/shCEBPA#1 cells showed 
64% reduction of CEBPA mRNA, while suppression in HL-60/shCEBPA#2 cells was only 
32% (Fig. 4D, upper left). When cells were treated with ICCB280 for 7 days, we observed 
that only 48% of HL-60/shCEBPA#1 cells were morphologically differentiated upon 
ICCB280 treatment, compared to 90% differentiation of HL-60/shCEBPA#2 and HL-60/
control shRNA cells (Fig. 4D). Taken together, our results demonstrate that ICCB280 
mediates granulocytic differentiation of AML cells by increasing the expression and activity 
of C/EBPα transcription factor.
ICCB280 and G-CSF cooperatively induce granulocytic differentiation
Upregulation of CSF3R by ICCB280 prompted us to hypothesize that cells treated with 
ICCB280 may be more susceptible to G-CSF and that a combination of ICCB280 and G-
CSF would enhance neutrophilic differentiation. As shown in Figure 5A, in the absence of 
ICCB280 HL60 cells did not respond to the treatment with G-CSF. However, when treated 
with ICCB280 together with G-CSF for 7 days, HL-60 cells showed morphology consistent 
with neutrophilic differentiation and N/C ratio was even lower than in cells treated with 
ICCB280 alone (Fig. 5A). In addition, flow cytometric analysis detected more surface 
CD11b-positive cells treated with ICCB280/G-CSF combination (47%), than G-CSF (6%) 
or ICCB280 (25%) alone (Fig. 5B). These results suggest that ICCB280 induces 
upregulation of G-CSFR, which renders leukemic cells more susceptible to G-CSF 
stimulation.
ICCB280 adopts a unique 3-dimentional conformation that affects its potency
In order to identify key structural attributes that are critical to the activity of ICCB280, we 
searched for its analogs. We identified 61 2-(2-arylvinyl)-3-aryl-4(3H)-quinazolinone 
analogs available at the Institute of Chemistry and Cell Biology (Harvard Medical School) 
and these compounds were screened at 10 μM each for induction of morphological changes 
and NBT positivity (Table S1). HL-60 cells were treated with each compound and stained 
with Wright Giemsa and NBT as in Figure 3C. Among all 61 analogs, 9 showed 
differentiation activity, but ICCB280 was the most potent (Fig. 6A). Structure comparisons 
indicate that the catechol moiety and the ortho-methoxy (MeO) group on the 3-phenyl ring 
are important for the high activity of ICCB280. In contrast, the meta-MeO (on the 3-phenyl 
ring) regioisomer of ICCB280 is far less active, while the para-isomer is completely 
inactive. We conducted conformational analyses of the three isomeric compounds (Fig. 6B). 
Although the position of the MeO group has only marginal effects on the torsional angle 
between the 3-phenyl ring and the quinazolinone ring (57.5° for ICCB280 vs. 52.1° and 
50.5° for the meta- and para-isomers, respectively), we observed a profound effect on the 
conformational change of the catechol moiety. While the catechol ring of the meta- and 
para-isomers remains essentially coplanar with the vinyl-quinazolinone, the catechol ring in 
ICCB280 has rotated nearly 60° away from a conjugated planar geometry. This significant 
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change is likely the cause of the othro-MeO group that is propelled toward the catechol 
electrostatically by the carbonyl group.
Discussion
Introduction of all-trans retinoic acid (ATRA) as the first-line therapy for t(15;17) positive 
acute promyelocytic leukemia has dramatically improved prognosis with a cure rate being 
nearly 70%.23 However, despite tremendous efforts made even prior to great success of 
ATRA, a differentiation therapy for other types of AML has been unavailable so far. Among 
the promising targets for differentiation therapy were two nuclear receptors, vitamin D 
receptor (VDR) and peroxisome proliferator activated receptor gamma (PPARγ), which 
were described to play crucial roles in induction of differentiation of leukemic cells.24 
However, neither vitamin D compounds, nor PPARγ agoinsts have shown clinical 
impacts.24 Thus, identification of a new strategy for differentiation therapy is still warranted.
Given that C/EBPα transcription factor plays a central role in myeloid differentiation 
program, here we describe a successful establishment of a cell-based high-throughput 
screening to identify novel chemical compounds that enhance C/EBPα expression and/or 
activity and thus induce granulocytic differentiation. We identified ICCB280 as a lead 
compound, which led to myeloid differentiation of leukemia cells morphologically and 
functionally, accompanied by increased expression/activity of C/EBPα and its downstream 
target genes. Importantly, we showed that ICCB280 indeed induced differentiation-like 
morphological changes and apoptosis in primary human acute leukemia cells from two 
patients with AML in this proof-of-principle study. In addition to its role in myeloid 
leukemia, we have shown that C/EBPα is necessary for lung alveolar cell development and 
downregulation of C/EBPα is detected in approximately half of primary human lung 
cancers.8, 25, 26 Thus, our C/EBPα-inducing strategy may find applications in treatment of 
solid tumors as well. Further studies are necessary to demonstrate clinical effectiveness and 
safety of this class of chemical compounds.
We demonstrated that ICCB280 exhibits anti-leukemic properties including terminal 
differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and 
affecting its downstream targets. One such target is C/EBPε, which is transcriptionally and 
directly regulated by C/EBPα and responsible for progression of later stages of granulocytic 
differentiation of myeloid cells.21 In addition to transcriptional transactivation of neutrophil-
specific genes, such as CD11b and G-CSFR, C/EBPα also hinders cell cycle progression by 
inhibiting cyclin-dependent kinase-2 (CDK2) through physical interaction with p21.27 
ICCB280-mediated inhibition of cell proliferation can be also explained by a dramatic 
downregulation of c-Myc by ICCB280, consistent with our previous report demonstrating C/
EBPα-mediated transcriptional downregulation of c-Myc gene expression.14 As Myc 
proteins contribute to cell proliferation by activating cell cycle and inducing DNA 
replication,28 our results indicate that downregulation of c-Myc contributes to ICCB280-
induced proliferation arrest. Furthermore, ICCB280 caused 80% reduction in cell growth in 
48 hours, whereas differentiation and apoptosis were observed at much later time (5–7 
days). These results indicate that growth arrest precedes differentiation and apoptosis 
induced by ICCB280.
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Although hematopoietic cytokines are essential for differentiation of normal hematopoietic 
stem and progenitor cells into mature cells, only modest effects are observed in leukemia 
cell lines or primary human AML cells, both in vitro and in vivo.24 One of the reasons may 
be lack of signals from G-CSF due to low expression of its receptor, G-CSFR. Indeed, G-
CSFR is restricted in a subset of myelomonocytic cell lines and shows considerable 
variability among primary AML blasts.29 We showed that ICCB280 induced up-regulation 
of G-CSFR in HL-60 cells, which do not express appreciable amounts of G-CSFR on the 
surface under normal conditions.29 It is of interest to note that G-CSF significantly enhanced 
ICCB280-induced differentiation of leukemia cells. Therefore, a combination of chemical 
compounds that induce C/EBPα activity and hematopoietic cytokines such as G-CSF makes 
it a plausible strategy to induce differentiation of leukemic blasts more effectively.
The biological activity of an organic compound depends on its interactions with its 
biological target, and this interplay is profoundly affected by stable 3 dimensional structures 
presented by the organic molecule. Our conformational analyses imply that ICCB280 adopts 
a unique spatial geometry that might be preferential for its high activity. We envision that 
the torsional angle and associated conformational change may prove to be critical 
parameters to guide future structure-activity relationship (SAR) study, which may result in 
novel compounds with improved activity.
In summary, we successfully established a cell-based high throughput screening to identify 
chemical compounds capable of inducing myeloid differentiation. Our data showing that 
ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient 
blasts strongly signify that the activity of this compound can overcome resistance to other 
current therapies for AML with unfavorable prognosis. It will be interesting to test the 
potential synergistic effect of ICCB280 and other agents affecting granulocytic 
differentiation, such as ERK1/2 or cdc2 inhibitors.13, 30 Finally, our data indicate that 
similar target-oriented drug screening approaches may be applied to other malignancies 
affecting different specific pathways. It is expected that identification of novel 
differentiation therapies will benefit patients with AML, who are resistant to current 
treatment in the near future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Establishment of the cell line which detect C/EBPa activity
(A) A firefly luciferase gene was placed under the control of tetramer of C/EBP binding 
sites from the human G-CSF receptor gene. U937 cell line was stably transfected with this 
construct, together with a neo-resistant gene. (B) CV-1 cells were transiently transfected 
with C/EBPα expression vector and the reporter shown above and luciferase activity was 
analyzed. Data represents mean ± standard deviation from three independent experiments. * 
indicates p ≤ 0.05. (C) Stable U937-C/EBP cells were treated with either 0.1% DMSO or 1 
μM ATRA for 24 hours. Luciferase activity was measured using a benchtop luminometer. 
Data represents mean ± standard deviation from three independent experiments. * indicates 
p ≤ 0.05.
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Figure 2. High-thourghput screening of chemical compounds that increase C/EBP expression 
and/or activity
(A) Stable U937-C/EBP cells were plated in a 384-well plate and treated with either 0.1% 
DMSO or 10 μM ATRA. Luciferase activity was measured using multiplate luminometer. 
Data represents mean ± standard deviation from three independent experiments. (B) The 
plate which contains a luminescence signal of ICCB280 (red arrow). A black arrow shows 
positive control.
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Figure 3. Identification of ICCB280
(A) Structure of ICCB280 (2-[2-(3,4-dihydroxyphenyl)vinyl]-3-(2-methoxyphenyl)-4(3H)-
quinazolinone). (B) HL-60 cells were treated with 10 μM ICCB280 or 0.1% DMSO for 7 
days and stained with Wright Giemsa (left panels) and NBT (right panels) (x40). (C) HL-60 
cells were plated in 96 plates and treated with 10μM ICCB280. After 48 hours, MTS assay 
was performed. Data represents mean ± standard deviation from four independent 
experiments. (D) HL-60 cells were treated with 10 μM ICCB280 or 0.1% DMSO for 
indicated period and stained with Annexin V and PI. Cells were then subjected to flow 
cytometric analysis. (E) Mononuclear cells were isolated from two patients with acute 
myeloid leukemia (#0502 and #0505) and treated with either 10 μM ICCB280 or 0.01% 
DMSO for 5 days. Cells were stained with Wright Giemsa (x40).
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Figure 4. ICCB280 leads to an increase in C/EBPα expression and modulates its target genes
(A) HL-60 cells were treated with 10 μM ICCB280 for indicated period. cDNAs were 
subjected to real-time PCR. CEBPA mRNA expression was normalized to the housekeeping 
gene GAPDH and is shown as n-fold changes compared to non-treated HL-60. Data 
represents mean ± standard deviation from three independent experiments. (B) HL-60 cells 
were treated with 10 μM ICCB280 or 0.1% DMSO for indicated period. Cell extracts were 
subjected to western blot analysis. (C) Total RNAs were isolated and subjected to northern 
blot analysis. (D) HL-60 cells were infected with lentiviral vectors containing shRNA 
against CEBPA (#1 or #2) or the scramble control. Reduction of CEBPA expression is 
shown compared to HL-60 treated with the scramble vector. Data represents mean ± 
standard deviation from three independent experiments (upper left). Cells were treated with 
10 μM ICCB280 for 7 days and stained with Wright Giemsa (x40).
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Figure 5. G-CSF enhances ICCB280 induced myeloid differentiation
HL-60 cells were treated with either 10 μM ICCB280 or 0.03% DMSO in the presence or 
absence of 6 μg/ml of G-CSF for 7 days. (A) Cells were stained with Wright Giemsa (x40). 
(B) Treated cells were stained with CD11b antibody and subjected to flow cytometric 
analysis.
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Figure 6. Conformational analyses of ICCB280
(A) ICCB280 was the most potent inducer of differentiation among 61 similar compounds. 
HL-60 cells were treated with each compound and stained with Wright Giemsa and NBT. 
(B) Overlay of the most energy-minimized conformers of ICCB280 (yellow), its meta- 
(green) and para-isomers (cyano). Hydrogen atoms are omitted except for the OH groups
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